#

Pharmaceutical Companies

: 119
The transaction gives Eli Lilly access to AtaiBeckley’s experimental drug being studied in phase III clinical trials for treatment-resistant depression / Photo: Shutterstock.com / Tada Images
News·
+1
·
Eli Lilly officially to acquire psychedelics drugmaker AtaiBeckley for $3.8 bln
Biogen shares fell following the release of results from Phase 2 trials of an Alzheimers drug / Photo: Shutterstock.com / JHVEPhoto
News·
Biogen shares fell after disappointing data on its Alzheimer's drug
Anthropic unveiled Claude Science, an AI platform for scientific research, and also announced the launch of preclinical drug development programs. Photo: Ousa Chea / Unsplash.com
Review·
Anthropic will focus on drug development. How can one profit from AI in the pharmaceutical sector?
Nike will release its quarterly results after the markets close on June 30 / Photo: Unsplash/Craig Lovelidge
News·
Morning in New York: Nike's Earnings Report and Negotiations Over the Strait of Hormuz Take Center Stage
Abivax Biotech Soars 36%: New Tests Allay Investors Fears / Photo: Abivax.com
News·
Abivax shares soared 36%. The company dispelled concerns about a cancer-causing drug
Shares of vaccine manufacturer Moderna hit their highest level since September 2024 / Photo: Panaceum Media / Shutterstock.com
News·
Moderna shares hit a two-year high after a 13% surge. It's all about a new treatment
Pfizers experimental lung cancer drug failed to extend patients survival / Photo: Flowersandtraveling / Shutterstock.com
News·
Pfizer's lung cancer drug trial has failed. What will happen to the stock?
AbbVie Acquires Psoriasis Drug Developer for $10.9 Billion / Photo: AbbVie
News·
AbbVie will acquire a psoriasis drug developer for $11 billion. Its stock rose 47%.
According to sources cited by the Financial Times, the pharmaceutical company AbbVie is preparing to acquire Apogee for $11 billion / Photo: abbvie.scene7.com
News·
AbbVie is preparing to acquire a dermatitis drug developer for $11 billion — FT
The head of Perplexity clarified the companys plans to go public in 2028 / Photo: miss.cabul / Shutterstock.com
Review·
Highlights for the morning: Iran threat, OpenAI and Perplexity's IPO plans, GSK's big deal
Eli Lillys new obesity drug led to weight loss by more than a quarter / Photo: Jonathan Weiss / Shutterstock.com
News·
'Eli Lilly pulls ahead': investors praise new obesity drug
Abivax shares collapsed nearly 30% after new data on its drug was released / Photo: abivax.com
News·
Shares of biotech Abivax plummet 30% after reports of cancer in trial participants
Load more